---
document_datetime: 2025-04-08 11:54:02
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lysodren-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lysodren-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1540283
conversion_datetime: 2025-12-18 22:53:20.475216
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Lysodren

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number      | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|-------------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Marketing Authorisation | - Transfer of a marketing authorisation - | 17/02/2025                          | 04/04/2025                                  | SmPC,                            |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Transfer - H / EMA/T/0000248630   | transfer of marketing authorisation from Esteve RD France S.A.S. to Esteve Pharmaceuticals S.A.   | Labelling and PL   |
|-----------------------------------|---------------------------------------------------------------------------------------------------|--------------------|